Effects of cyclical etidronate therapy on bone loss in early postmenopausal women who are not undergoing hormonal replacement therapy

Osteoporosis International

Volumn 7, Issue 3, 1997, Pages 213-218

  Pouilles, J M ^a   Tremollieres, F ^a   Roux, C ^b   Sebert, J L ^c   Alexandre, C ^d   Goldberg, D ^e   Treves, R ^f   Khalifa, P ^g   Duntze, P ^h   Horlait, S ^h   Delmas, P ⁱ   Kuntz, D ^j  

^a CHU PURPAN   (France)

^b Université Paris Descartes   (France)

^c AMIENS UNIVERSITY HOSPITAL   (France)

^d SERVICE DE NEUROLOGIE   (France)

^e Fondation Rotschild   (France)

^f DUPUYTREN UNIVERSITY HOSPITAL   (France)

^g Procter and Gamble Pharmaceuticals ^*  (France)

^h PROCTER AND GAMBLE COMPANY   (United States)

ⁱ EDOUARD HERRIOT HOSPITAL   (France)

^j CENTRE VIGGO PETERSEN   (France)

more..

Author keywords

Bone mineral density; Dual energy X ray absorptiometry; Etidronate; Postmenopausal bone loss; Postmenopausal osteoporosis

Indexed keywords

ALKALINE PHOSPHATASE; AMINO TERMINAL TELOPEPTIDE; CALCIUM; CREATININE; ETIDRONIC ACID; HYDROXYPROLINE; OSTEOCALCIN; PEPTIDE; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ADULT; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; BONE ATROPHY; BONE DENSITY; BONE MINERAL; BONE TURNOVER; CALCIUM INTAKE; CALCIUM URINE LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORTICAL BONE; CREATININE URINE LEVEL; DIET SUPPLEMENTATION; DIGESTIVE SYSTEM FUNCTION DISORDER; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG SAFETY; DRUG TOLERABILITY; DUAL ENERGY X RAY ABSORPTIOMETRY; ESOPHAGITIS; FEMALE; FEMUR NECK; GASTRITIS; GASTROINTESTINAL SYMPTOM; HORMONE SUBSTITUTION; HUMAN; HYDROXYPROLINE URINE LEVEL; LUMBAR SPINE; MAJOR CLINICAL STUDY; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PATIENT COMPLIANCE; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; TRABECULAR BONE; URINE LEVEL;

ALKALINE PHOSPHATASE; BIOLOGICAL MARKERS; COLLAGEN; COLLAGEN TYPE I; CREATININE; ETIDRONIC ACID; FEMALE; FRACTURES, SPONTANEOUS; HUMANS; LUMBAR VERTEBRAE; MIDDLE AGED; OSTEOCALCIN; OSTEOPOROSIS, POSTMENOPAUSAL; PEPTIDES;

EID: 8244264293     PISSN: 0937941X     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF01622291     Document Type: Article

References (20)

1. Hui SL, Slemenda CW, Johnston CC Baseline measurement of bone mass predicts fracture in white women. Ann Intern Med 1989;111:355-61.
2. Melton LJ, Atkinson EJ, O'Fallon WM, et al. Long-term fracture prediction by bone mineral assessed at different skeletal sites. J Bone Miner Res 1993;8:1227-33.
3. Cummings SR, Nevitt MC, Browner WS, et al. Risk factors for hip fractures in white women. Study of Osteoporotic Fractures Group. N Engl J Med 1995;332:767-73.
4. Black DM, Cummings SR, Gennant HK, et al. Axial and appendicular bone density predict fractures in older women. J Bone Miner Res 1992;7:733-8.
5. Christiansen C. The different routes of administration and the effect of hormone replacement therapy on osteoporosis. Fertil Steril 1994;62:152S-6S.
6. Ettinger B, Genant HK, Cann CE. Long-term estrogen replacement therapy prevents bone loss and fractures. Ann Intern Med 1985;102:319-24.
7. Felson DT, Zhang Y, Hannan MT, et al. The effect of postmenopausal estrogen therapy on bone density in elderly women. N Engl J Med 1993;329:1141-6.
8. Sagraves R. Estrogen therapy for postmenopausal symptoms and prevention of osteoporosis. J Clin Pharmacol 1995;35:S2-10.
9. Griffing GT, Allen SH. Estrogen replacement therapy at menopause. How benefits outweigh risks. Postgrad Med 1994;96(5):131-40.
10. Colditz GA, Hankinson SE, Hunter DJ, et al. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women (see comments). N Engl J Med 1995;332:1589-93. Note: comment in N Engl J Med 1995;332:1638.
11. Papapoulos SE. The role of bisphosphonates in the prevention and treatment of osteoporosis. Am J Med 1995;10:315-24.
12. Fleisch H. The use of bisphosphonates in osteoporosis. Br J Clin Pract 1994;48:323-6.
13. Storm T, Thamsborg G, Steiniche T, et al. Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis. N Engl J Med 1990;322:1265-71.
14. Watts NB, Harris ST, Genant HK, et al. Intermittent cyclical etidronate treatment of postmenopausal osteoporosis N Engl J Med 1990;323:73-9.
15. Harris ST, Watts NB, Jackson RD, et al. Four-year study of intermittent cyclic etidronate treatment of postmenopausal osteoporosis: three years of blinded therapy followed by one year of open therapy. Am J Med 1993;95:557-67.
16. Herd RJM, Blake GM, Ryan PJ, et al. A 152 patient double blind placebo controlled study of cyclical etidronate therapy for the prevention of early postmenopausal bone loss. J Bone Miner Res 1995;10:5153.
17. Meunier PJ, Confavreux C, Tupinon I, et al. Cyclical etidronate therapy prevents bone loss in the early postmenopausal period. J Bone Miner Res 1995;10:S357.
18. Reginster JY Deroisy R, Denis D, Colette J, Lecart MP, Sarlet N, Ethgen D, Franchimont P. Prevention of postmenopausal bone loss by tiludronate. Lancet 1989; 2:1469-71.
19. Filliponi P, Pedetti M, Fedeli L, et al. Cyclical clodronate is effective in preventing postmenopausal bone loss: a comparative study with transcutaneous hormone replacement therapy. J Bone Miner Res 1995;10:697-703.
20. Eisman JA, Christiansen C, McClung M, et al. Alendronate prevents bone loss at the spine and hip in recently postmenopausal women. J Bone Miner Res 1995;10:S176.